CSE:PHRX - Post Discussion
Post by
Blahblahblahbla on Apr 11, 2022 6:39pm
Looks like more news coming soon
PharmaDrug advances DMT-analogue glaucoma program with fabrication of medical device
PharmaDrug Inc CEO Daniel Cohen tells Proactive it has successfully completed the fabrication of a novel medical device capable of delivering sustained, low quantities of a tryptamine-based pharmaceutical to the front of the eye, with the intended purpose to potentially lower intraocular pressure in patients suffering from glaucoma. Additionally, the company said a head-to-head drug elution study of its three undisclosed DMT-analogue candidates has now been completed while supportive cell-based biocompatibility has been examined for all three candidate molecules.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
This record is published on behalf of Pharmadrug Inc, which is a paid client of paidpromotionalmessages. You understand that paidpromotionalmessages receives either monetary or securities compensation for our services,...
paidpromotionalmessages is a publisher. You understand and agree that no content in this record or published on paidpromotionalmessages’ website (the “Site”) constitutes a recommendation that any particular security,...
FOR OUR FULL DISCLAIMER CLICK HERE
Be the first to comment on this post